Antibody-Drug Conjugates in Specific Subsets of NSCLC - 2024 Lung Cancer OncTalk

The 2024 Lung Cancer OncTalk was a live, virtual, interactive patient education event presented in December 2024 and led by Dr. Ibiayi Dagogo-Jack. It included presentations and panel discussions covering general subjects relevant to lung cancer and treatment options and an opportunity to speak with the experts in a Q&A session. Speakers included top medical professionals presenting patient-focused discussions to educate the patient and caregiver communities to become advocates for their own health and well-being. In this video, Dr. Cooper discusses how antibody-drug conjugates (ADCs) apply to selected populations (specific subsets) of non-small cell lung cancer (NSCLC) such as EGFR-mutations and c-MET IHC+. She specifically discusses ADCs such as patritumab deruxtecan and telisotuzumab vedotin and trials that could show if the combination of these drugs with standard therapies could improve efficacy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Music: Creative Minds (BenSound) Licence: WLVYBP2ARGGSGUQQ